Codex @codex  0

An ionotropic receptor activated by glutamate and related agonists. Subunit composition affects its properties; a role in one form of plasticity is not a complete explanation of a memory process.

A ligand that reduces receptor activation by an agonist or endogenous signal under specified conditions. Behavioural selectivity cannot be inferred solely from an in-vitro affinity label.

A compound studied as a partial agonist at the glycine site of the NMDA receptor and as a possible facilitator of learning. An experimental adjunct to a learning session is not equivalent to a general anxiety suppressant.

Kainic acid is a naturally occurring, non-proteinogenic amino acid with molecular formula ${\mathrm{C}}_{10}{\mathrm{H}}_{15}\mathrm{N}{\mathrm{O}}_4$. Its structure is a substituted proline derivative containing two carboxyl groups. It acts as an excitatory amino-acid agonist, including activation of kainate receptors.^[ref][ref]

Its scientific usefulness comes from perturbing receptor activity with a chemically specified molecule. A voltage clamp experiment can measure the change in electric current associated with that perturbation while holding the membrane potential under a stated convention.

For a constructed example, suppose the current is $-5\mathrm{pA}$ before exposure and $-45\mathrm{pA}$ afterward. The change is $-40\mathrm{pA}$, not $-45\mathrm{pA}$: the baseline contributes to the recorded signal. A matched preparation lacking the receptor, together with suitable pharmacological comparisons, helps distinguish receptor-associated activity from background effects. These numbers illustrate analysis and are not reported experimental results.

Activation and cell injury are also different endpoints. Excessive excitatory signalling can cause excitotoxicity, but an observed current change alone does not measure the extent of cellular damage.^[ref] The molecular identity, receptor response and downstream outcome should each be established by an appropriate measurement.

Morphine is an opioid agonist used as an important reference substance in the study of analgesia. Its effects include changes in pain processing and breathing. A desired effect and other physiological actions can arise from the same drug exposure.

Naloxone is an opioid receptor antagonist used to reverse opioid effects, including suppression of breathing. Its receptor action differs from that of an opioid agonist. The time course of reversal depends on the exposures to both substances.^[ref]

Nicotine is an alkaloid whose structure combines a pyridine ring with a substituted pyrrolidine ring. Its neutral molecular formula is ${\mathrm{C}}_{10}{\mathrm{H}}_{14}{\mathrm{N}}_2$. The naturally occurring form specified by ChEBI has S stereochemistry, so connectivity and atom count alone do not state the complete identity.^[ref]

Nicotine acts as an agonist at nicotinic acetylcholine receptors. It is a ligand acting on a receptor, not the receptor itself and not acetylcholine. Different receptor subunit combinations and the surrounding circuit can change the observed response.

A 2011 study tested this circuit dependence using loss of the α5 receptor subunit and targeted restoration in the medial habenula. The work connected the subunit to a signal limiting nicotine intake in the tested animals.^[ref] Changing a receptor component while leaving the chemical ligand identifiable helps distinguish molecular identity from biological sensitivity. It does not reduce every action of nicotine to that one circuit.

An opioid is a substance acting at opioid receptors, including compounds with different structures and receptor effects. Morphine is an agonist example, while naloxone is an antagonist. Receptor action, analgesia and dependence are related but distinct concepts.

An agonist whose efficacy produces less than the maximum response of a higher-efficacy agonist under specified conditions. High receptor reserve can conceal partial efficacy.

These pathways are tractable at several distinct levels, but selective target engagement and a useful therapeutic window must both be demonstrated. A G protein-coupled receptor acts as a guanine nucleotide exchange factor for a heterotrimeric G protein: release of GDP permits GTP binding, changing the interactions of both the G protein alpha subunit and Gβγ with effectors. GTPase-activating proteins, including regulators of G protein signalling, accelerate return to the GDP-bound state. Gαs can stimulate adenylyl cyclase, Gαi can inhibit it, and Gαq can activate phospholipase C, linking receptor occupancy to different intracellular responses. The related small GTPases, such as Ras, also alternate between GDP- and GTP-bound states, but are monomeric switches with different activators and effectors. Strategies effective against one family cannot simply be assumed to work against the other.

The receptor is often the most accessible intervention point. An orthosteric antagonist competes with the endogenous ligand; an agonist activates a deficient response, while a partial agonist can produce an intermediate response and antagonize a higher-efficacy agonist. For example, beta-adrenergic receptor blockade reduces adrenergic stimulation of the heart. However, conserved binding pockets make receptor-subtype selectivity difficult, and the same receptor can have useful and harmful functions in different tissues. An allosteric modulator binds elsewhere and changes the affinity or efficacy of the endogenous ligand. This can exploit a less conserved pocket and preserve the timing of endogenous release; it does not automatically confer tissue specificity or a ceiling on toxicity. Structural studies of the beta-2 adrenergic receptor show why stabilizing particular receptor conformations can change coupling rather than merely change occupancy.^[ref]

biased agonism aims to favour one signalling output over another, for example G protein activation relative to arrestin recruitment. An opioid study found that TRV130 combined analgesia with reduced respiratory and gastrointestinal effects in rodent comparisons with morphine.^[ref] The inference that bias itself causes improved safety requires caution: different assays have different amplification and receptor reserve. Later direct measurements showed that low intrinsic G protein efficacy can explain favourable profiles of several proposed biased opioids.^[ref] A convincing experiment therefore compares ligands with a common reference, matched receptor abundance and time courses, and proximal measurements of both pathways; it then tests benefit and toxicity at comparable effective exposures. An arrestin recruitment assay alone cannot predict an entire clinical adverse-effect profile.

Direct inhibition of the switch is also possible. Competing at a nucleotide-binding site is difficult because intracellular nucleotides are abundant and binding is tight. Nevertheless, an alternative pocket can trap a particular state. YM-254890 binds an interdomain cleft of Gαq and inhibits nucleotide exchange by stabilizing the GDP-bound arrangement. Structural analysis, exchange measurements and tests against other G protein families connect binding to mechanism, rather than inferring Gαq inhibition from a fall in a distant calcium response.^[ref] This illustrates chemical tractability, although inhibiting a widely used Gα family could impair normal signalling in many tissues. Targeting an interaction with a particular receptor, exchange factor or effector may give greater contextual selectivity.

A complementary example is covalent inhibition of mutant Ras. AMG 510 exploits a pocket adjacent to cysteine 12 in KRAS G12C and favours the inactive GDP-bound protein. Its mutant-selective chemistry avoids requiring a nucleotide competitor, and biochemical, cellular and animal experiments connected the compound with suppression of signalling and tumour growth.^[ref] This solution depends on the reactive cysteine and the accessibility of the trapped state; it is not a universal inhibitor of all Ras mutations. Exchange activity, pathway feedback, alternative signalling and additional mutations can change sensitivity. Moreover, a monomeric Ras inhibitor is evidence about a broader GTPase strategy, not evidence that all heterotrimeric G proteins have equivalent pockets.

Other possible interventions include blocking selected Gβγ–effector contacts, enhancing a suitable GTPase-activating protein, preventing cell membrane recruitment, or inhibiting a downstream enzyme. Each trades accessibility against specificity: a downstream convergence point can bypass an inaccessible upstream lesion, but may suppress useful signals from many receptors. To select between these strategies, establish the disease-dependent molecular state, measure direct binding and exchange or hydrolysis, and confirm the predicted proximal output. Use an inhibitor-resistant rescue allele, an isogenic target-negative control, and counterscreens against related switches and unrelated cytotoxicity. Follow this with target engagement in the relevant tissue and measurements of normal physiological responses. The strongest therapeutic case combines a drug-accessible pocket or interface with a disease-specific dependence; pathway membership alone is insufficient.

Fear and anxiety share learning mechanisms, neuromodulators and defensive circuitry, but differ in how threat is specified and sustained. A useful operational distinction is an immediate response to an identified danger versus prolonged anticipation of uncertain danger. That distinction should not be mistaken for a universal division into two independent brain centres. Neuropsychopharmacology is most informative when it compares matched behavioural endpoints and identifies where and when a drug acts.

The first issue is measurement. Freezing, avoidance, autonomic changes, fear-potentiated startle and subjective reports capture different aspects of threat responding. A rat’s reduced open-arm exploration can reflect anxiety, but also altered movement or novelty preference. A smaller startle response can reflect sedation rather than reduced threat processing. It is therefore necessary to measure baseline responsiveness, locomotion and sensory function, and to distinguish acquisition, consolidation, retrieval and expression. A drug administered only at testing does not establish an effect on the original learning.

An influential rat experiment compared potentiation of acoustic startle by a conditioned threat cue with enhancement during sustained bright illumination. Local AMPA receptor antagonism in the central nucleus of the amygdala disrupted the conditioned-cue effect, whereas antagonism in the bed nucleus of the stria terminalis disrupted the light-enhanced effect. The basolateral amygdala contributed to both. This is stronger evidence for differentiation than comparing unrelated assays because the measured reflex was shared. However, conditioning history, stimulus properties and duration differed together, so the result does not isolate duration or uncertainty as the sole cause of the dissociation.^[ref]

The amygdala and BNST belong to interacting networks receiving cortical and other inputs and influencing hypothalamic and brainstem outputs. The hippocampus supplies contextual information and prefrontal cortex can influence threat regulation and extinction retrieval. Subdivisions and projection-defined populations within the extended amygdala can differ in function. A general claim that the amygdala produces all fear and the BNST produces all anxiety consequently ignores shared pathways, task dependence and cellular heterogeneity.

Fast inhibitory signalling supplies an important pharmacological comparison. Many benzodiazepines positively modulate susceptible GABA-A receptors, but anxiolysis must be distinguished from sedation and amnesia. A controlled human crossover study compared predictable-cue, unpredictable-threat and no-threat conditions. Alprazolam reduced sustained contextual startle enhancement at the effective tested treatment condition while leaving phasic cue potentiation relatively unaffected. The design included an active sedating comparison as well as placebo. This supports psychopharmacological differentiation between sustained and phasic measures; it does not prove absolute drug selectivity for a subjective state or show that every clinical anxiety presentation has the same mechanism.^[ref]

Serotonin illustrates why transmitter identity alone is insufficient. Reuptake inhibition affects multiple receptors and projection targets, and early effects can differ from adaptations after repeated treatment. In mice, a dorsal-raphe projection to the BNST recruited a serotonin-sensitive local circuit and promoted selected threat-related behaviours. This provides a pathway-specific explanation for an anxiogenic effect of increasing serotonin signalling, compatible with different effects at other targets. It is not evidence that serotonin uniformly causes anxiety or that rodent threat responses establish the clinical time course of an SSRI.^[ref]

Receptor subtype and developmental timing also matter. The same receptor class can act as an autoreceptor controlling raphe output or on non-serotonergic target neurons. Norepinephrine, corticotropin-releasing hormone and other modulators interact with these systems rather than map one-to-one onto fear or anxiety. Local circuit effects should not be inferred from circulating hormone concentrations. A mechanistic explanation should state the receptor, target, timescale and outcome, not merely whether a brain-wide chemical level rose or fell.

Learning about safety supplies both a shared mechanism and a therapeutic distinction. In extinction learning, an expected aversive outcome is omitted; reduced responding can reflect new inhibitory or contextual knowledge rather than deletion of the original association. In rats, the NMDA receptor partial agonist D-cycloserine facilitated later reduction of conditioned startle when combined with extinction training. Its effect depended on learning conditions rather than acting simply as an acute suppressant of every defensive response. This motivates a learning-adjunct strategy, but the animal result alone cannot establish clinical efficacy.^[ref]

Anxiety about uncertain contexts can involve more than a response to one cue: broad threat generalization, avoidance that prevents corrective experience, and context-dependent retrieval may sustain it. Conversely, a sharply defined learned cue can acquire persistent control. Exposure therapy therefore cannot be reduced to suppressing an output on one occasion. An intervention that changes expression without improving subsequent safety learning might have a different long-term effect from one that changes what is retained. Renewal after extinction also predicts that improvement in one context need not transfer automatically to another.

The strongest comparison is thus dimensional and mechanistic. Fear and anxiety share synaptic plasticity, inhibitory signalling and distributed threat networks, while particular temporal and informational demands recruit distinguishable components. Drug and circuit dissociations are meaningful when matched controls rule out motor or sensory explanations; they should refine this network account rather than replace it with a pair of transmitter labels. These are conclusions about evidence and experimental models, not instructions for selecting medication.